PMID- 19275472
OWN - NLM
STAT- MEDLINE
DCOM- 20091027
LR  - 20220316
IS  - 1937-335X (Electronic)
IS  - 1937-3341 (Linking)
VI  - 15
IP  - 9
DP  - 2009 Sep
TI  - B-type natriuretic peptide enhances vasculogenesis by promoting number and 
      functional properties of early endothelial progenitor cells.
PG  - 2741-9
LID - 10.1089/ten.TEA.2008.0414 [doi]
AB  - OBJECTIVE: To test the hypothesis that B-type natriuretic peptide (BNP) acts as a 
      potent vasculogenic agent by enhancing the number, proliferation, adhesion, and 
      migration of endothelial progenitor cells (EPCs). BACKGROUND: BNP is a 
      neurohormonal peptide that predicts outcome and used for treatment in chronic 
      heart failure patients. It has been shown to promote angiogenesis in experimental 
      animals. EPCs have been demonstrated to contribute to postnatal angiogenesis and 
      vasculogenesis. METHODS: The number of EPC colony forming units (CFU) and levels 
      of N-terminal ProBNP were assayed in patients with severe, yet controlled, New 
      York Heart Association (NYHA) II-IV heart failure. The in vitro effects of BNP on 
      early EPC-CFU numbers, proliferation, migration, adhesive, and vascular tube 
      formation capacities were studied using human and murine systems. The effects of 
      in vivo BNP administration on Sca-1/Flk-1 progenitors and on vasculogenesis in 
      the hindlimb ischemia model were then assayed in wild-type mice. RESULTS: A 
      significant correlation was found between circulating N-terminal ProBNP levels 
      and EPC-CFU numbers. We observed a dose-dependent effect of BNP on the numbers of 
      CFU and proliferation capacity of human EPCs as well as on their adhesive, 
      migratory, and tube formation properties, in vitro. Systemic BNP administration 
      to mice led to a significant increase in bone marrow Sca-1/Flk-1 EPCs and 
      improvement in blood flow and capillary density in the ischemic limbs of mice. 
      CONCLUSIONS: BNP promotes vessel growth by increasing the number of endothelial 
      progenitors and enhancing their functional properties. These provasculogenic 
      properties of BNP could account for some of its beneficial effects in chronic 
      heart failure patients and may be harnessed for the purpose of improving 
      collateral formation in ischemic subjects.
FAU - Shmilovich, Haim
AU  - Shmilovich H
AD  - Department of Cardiology, Tel Aviv Sourasky Medical Center, Sackler School of 
      Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Ben-Shoshan, Jeremy
AU  - Ben-Shoshan J
FAU - Tal, Reshef
AU  - Tal R
FAU - Afek, Arnon
AU  - Afek A
FAU - Barshack, Iris
AU  - Barshack I
FAU - Maysel-Auslander, Sofia
AU  - Maysel-Auslander S
FAU - Harats, Dror
AU  - Harats D
FAU - Keren, Gad
AU  - Keren G
FAU - George, Jacob
AU  - George J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
RN  - 0 (ATXN1 protein, human)
RN  - 0 (Ataxin-1)
RN  - 0 (Ataxins)
RN  - 0 (Atxn1 protein, mouse)
RN  - 0 (Drug Combinations)
RN  - 0 (Laminin)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Proteoglycans)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 119978-18-6 (matrigel)
RN  - 9007-34-5 (Collagen)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.10.1 (Vascular Endothelial Growth Factor Receptor-1)
SB  - IM
MH  - Animals
MH  - Ataxin-1
MH  - Ataxins
MH  - Bone Marrow Cells/cytology/drug effects
MH  - Cell Adhesion/drug effects
MH  - Cell Count
MH  - Cell Movement/drug effects
MH  - Collagen/metabolism
MH  - Colony-Forming Units Assay
MH  - Drug Combinations
MH  - Endothelial Cells/*cytology/drug effects/enzymology
MH  - Heart Failure/blood
MH  - Humans
MH  - Ischemia
MH  - Laminin/metabolism
MH  - Mice
MH  - Natriuretic Peptide, Brain/administration & dosage/blood/*metabolism/pharmacology
MH  - Neovascularization, Pathologic/metabolism
MH  - *Neovascularization, Physiologic/drug effects
MH  - Nerve Tissue Proteins/metabolism
MH  - Nuclear Proteins/metabolism
MH  - Peptide Fragments/blood
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Proteoglycans/metabolism
MH  - Stem Cells/*cytology/drug effects/enzymology
MH  - Vascular Endothelial Growth Factor Receptor-1/metabolism
EDAT- 2009/03/12 09:00
MHDA- 2009/10/29 06:00
CRDT- 2009/03/12 09:00
PHST- 2009/03/12 09:00 [entrez]
PHST- 2009/03/12 09:00 [pubmed]
PHST- 2009/10/29 06:00 [medline]
AID - 10.1089/ten.TEA.2008.0414 [doi]
PST - ppublish
SO  - Tissue Eng Part A. 2009 Sep;15(9):2741-9. doi: 10.1089/ten.TEA.2008.0414.